A process treats the health risk associated with the presence of raised quantities of C-reactive protein (CRP). The treatment employs extra-corporal perfusion of blood plasma in a patient with a cardio-vascular condition. The treatment employs an assembly e.g. a column containing a matrix of an absorbent material e.g. lipids, peptides, polypeptides, phosphocholin (PC) or PC-derivates.